Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL Inc has experienced a significant stock appreciation of nearly 90% over the last month, reflecting increased investor confidence bolstered by promising data from the PATHFINDER 2 ESMO study. The company is projected to tap into a large total addressable market (TAM) estimated at approximately $3.7 billion in the UK by 2026 and growing to about $4.0 billion by 2035, driven by its multi-cancer early detection blood test and strategic partnerships. Despite uncertainties regarding FDA approval and Medicare reimbursement, the positive study results and a substantial balance sheet enhancement of over $400 million contribute to a bullish outlook on GRAIL's future growth potential.

Bears say

GRAIL Inc has consistently recorded significant net losses since its inception and anticipates ongoing financial difficulties as it pursues regulatory approvals and expands its facilities. The company faces multiple risks, including potential delays in Congressional actions regarding reimbursement for its multi-cancer early detection (MCED) tests, headwinds in market adoption, and competitive pressures from established diagnostics companies with greater scale and resources. Additionally, increased selling, general, and administrative expenses related to growing Galleri volumes, alongside potential challenges in securing necessary financing for product commercialization, further exacerbate GRAIL's negative outlook.

GRAIL Inc (GRAL) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 3 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.